ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
APOE ɛ4 carriership determines a faster plasma p-tau217 progression in Aβ-positive individuals.
Abstract read
In one paragraph
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Plasma phosphorylated tau 217 concentrations, APOE genotype, and timing of cognitive impairment in individuals across diverse racial and ethnic groups: a pooled analysis of prospective cohort studies.The Lancet. Neurology · 2026Article
- Predicting Preclinical Cognitive Decline Using Plasma P-tau217 andmedRxiv : the preprint server for health sciences · 2026Article
- Translating blood-based biomarkers into Alzheimer's disease clinical practice: screening, diagnosis, and longitudinal monitoring.Frontiers in aging neuroscience · 2026Review
- APOE ɛ4 carriership determines a faster plasma p-tau217 progression in Aβ-positive individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Marcel S WooTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.ORCID 0000-0002-1306-2708
Arthur C MacedoTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Seyyed Ali HosseiniTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Joseph TherriaultTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Yi-Ting WangTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Nesrine RahmouniTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Étienne AumontTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Stijn ServaesTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Cécile TissotDepartment of Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, California, USA.
Jaime Fernandez-AriasTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Lydia TrudelTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Brandon HallTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Gleb BezginTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Kely Quispialaya-SocualayaTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Marina GoncalvesTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Tevy ChanTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Jenna StevensonTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Yansheng ZhengTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Robert HopewellTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Stuart MitchellTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Firoza Z LussierDepartment Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Paolo VitaliTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Gassan MassarwehTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Jean-Paul SoucyTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Andréa L BenedetDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Serge GauthierTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Tharick A PascoalDepartment Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Pedro Rosa-NetoTranslational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada.
Funding
AD Strategic Fund and the Alzheimer's Association #ADSF-21-831376-CAD Strategic Fund and the Alzheimer's Association #ADSF-21831377-CAD Strategic Fund and the Alzheimer's Association #ADSF-21-831381-CAD Strategic Fund and the Alzheimer's Association #ADSF-24-1284328-CAD Strategic Fund and the Alzheimer's Association Bluefield Project Cure Alzheimer's Fund the Olav Thon Foundation the Erling-Persson Family Foundation Familjen Rönströms Stiftelse Stiftelsen för Gamla Tjänarinnor Hjärnfonden SwedenAD Strategic Fund and the Alzheimer's Association #FO2022-0270Alzheimer Drug Discovery Foundation (ADDF), USA #201809-2016862Alzheimer's Association 2022-2025 SG-23-1038904 QCBrain Canada Foundation 33397Brain Canada Foundation CFI Project 34874Canadian Consortium of Neurodegeneration and Aging MOP-1151-31Corona Foundation S0199/10110/2025Else-Kröner-Fresenius Foundation 2023_EKMS.03European Union Joint Program for Neurodegenerative Disorders JPND2019-466-236European Union Joint Programme - Neurodegenerative Disease Research JPND2021-00694European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie 860197European Union's Horizon Europe research and innovation programme 101053962Fonds de Recherche du Québec - Santé 2020-VICO-279314Hjärnfonden, Sweden #ALZ2022-0006Hjärnfonden, Sweden #FO2017-0243MSW receives additional funds from the German Research Foundation WO 2835/1-1National Institute for Health and Care Research University College London (UCL) Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL UKDRI-1003Swedish Alzheimer Foundation #AF930351Swedish Alzheimer Foundation #AF-939721Swedish Alzheimer Foundation #AF-968270Swedish State Support for Clinical Research #ALFGBG-71320Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement #ALFGBG-715986Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement #ALFGBG-965240the Alzheimer's Association NIRG-12-92090the Alzheimer's Association NIRP-12-259245the Alzheimer's Association 2021 Zenith Award ZEN-21-848495the Swedish Research Council #2017-00915the Swedish Research Council #2019-02397the Swedish Research Council #2022-00732the Swedish Research Council #2022-01018the Swedish Research Council #2023-00356Weston Brain Institute, Canadian Institutes of Health Research (CIHR; 159815Weston Brain Institute, Canadian Institutes of Health Research (CIHR; 162303Weston Brain Institute, Canadian Institutes of Health Research (CIHR; MOP-11-51-31Weston Brain Institute, Canadian Institutes of Health Research (CIHR; RFN 152985
Abstract
introductionIt is unclear whether the different Alzheimer's disease (AD) progression trajectories of apolipoprotein E (APOE) ɛ4 carriers is reflected by blood phosphorylated tau (p-tau) analytes.
methodsWe assessed longitudinal trajectories in plasma p-tau181, 217, and 231, in amyloid beta-positive (A+) and negative (A-) APOE ɛ4 carriers (E+) or non-carriers (E-). We included 2039 participants from the observational Translational Biomarkers in Aging and Dementia (TRIAD) and Alzheimer's Disease Neuroimaging Initiative cohorts, categorized into 840 A-E-, 251 A-E+, 386 A+E4-, and 616 A+E4+. Longitudinal data were available for 1045 participants.
resultsIn TRIAD, ALZpath p-tau217 (β = 0.45, p = 0.02) and p-tau217+ DISCUSSION: These findings suggest p-tau217 as a marker of faster progression in APOE ɛ4 carriers, highlighting its potential in disease stratification. HIGHLIGHTS: Blood phosphorylated tau (p-tau)217 increases faster in apolipoprotein E (APOE) ɛ4 carriers with amyloid pathology. p-tau181 and p-tau231 do not increase faster in APOE ɛ4 carriers. APOE ɛ4 carriership does not change p-tau in individuals without amyloid pathology.
Indexed as
Alzheimer DiseaseAmyloid beta-PeptidesApolipoprotein E4tau ProteinsAgedAged, 80 and overBiomarkersDisease ProgressionFemaleHeterozygoteHumansLongitudinal StudiesMalePhosphorylationAmyloid beta-PeptidesApolipoprotein E4Biomarkerstau ProteinsAlzheimer's diseaseapolipoprotein Ebiomarkerdisease progressionphosphorylated tau217
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.